Last reviewed · How we verify
Intravenous Glucocorticoids
Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR) in the cytoplasm.
Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR) in the cytoplasm. Used for Treatment of acute lymphoblastic leukemia.
At a glance
| Generic name | Intravenous Glucocorticoids |
|---|---|
| Also known as | Methylprednisolone |
| Sponsor | Guangzhou JOYO Pharma Co., Ltd |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This binding causes a conformational change in the GR, which then translocates to the nucleus and regulates gene expression by binding to specific DNA sequences.
Approved indications
- Treatment of acute lymphoblastic leukemia
Common side effects
- Hypertension
- Hyperglycemia
- Osteoporosis
Key clinical trials
- A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head (PHASE2)
- Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery (NA)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis (PHASE2)
- A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab (PHASE4)
- A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (PHASE3)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Glucocorticoids CI brief — competitive landscape report
- Intravenous Glucocorticoids updates RSS · CI watch RSS
- Guangzhou JOYO Pharma Co., Ltd portfolio CI